SOLV vs SYK vs EW Stock Comparison

Solventum, Stryker and Edwards Lifesciences Prices as of Nov 13, 2026 Peers: Industry group
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.13B
P/E
97.5x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
1 win
SYK Stryker Corp
$309.54 +9.9% 1M -17.1% 1Y
Market cap
$117.84B
P/E
32.7x
Revenue (TTM)
$26.30B
Div. yield
1.14%
Medical Devices Healthcare
4 wins
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.69B
P/E
60.9x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

11 decided of 12

Edwards Lifesciences leads on 6 of the 12 questions below (Edwards Lifesciences 6, Stryker 4, Solventum 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSOLVSYKEWLeader
Larger companyMarket capitalisation $15.13B $117.84B $61.69B SYK
Cheaper on earningsLower P/E, profitable companies only 97.5x 32.7x 60.9x SYK
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.8x 19.6x 37.6x SOLV
Faster revenue growthRevenue growth, trailing twelve months -2.8% +7.9% +13.4% EW
More profitableNet margin, trailing twelve months 1.9% 13.8% 15.2% EW
Better return on capitalReturn on invested capital 4.2% 10.0% 8.7% SYK
Less leveragedLower net debt / EBITDA 4.7x 3.5x -2.5x EW
Higher dividend yieldTrailing dividend yield — 1.14% — –
Better 1-year returnPrice return, last 12 months +18.4% -17.1% +24.5% EW
Better 5-year returnAnnualised price return, 5 years — +3.2%/yr -1.6%/yr SYK
Less volatileAnnualised volatility, 1 year 30.1% 32.9% 25.5% EW
Higher overall scoreMean of the five percentile scores vs peers 51/100 67/100 77/100 EW

Percentile Scorecard

SOLVSYKEW

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSOLVSYKEW
Valuation 70 #74 of 243 66 #84 of 243 61 #96 of 243
Growth 3 #221 of 228 63 #85 of 228 57 #99 of 228
Profitability 71 #66 of 222 88 #28 of 222 96 #10 of 222
Financial Health 15 #210 of 248 42 #144 of 248 87 #34 of 248
Shareholder Returns 94 #10 of 158 78 #35 of 158 84 #26 of 158
Overall 51 67 77
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • SYK ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSOLVSYKEWSPY
1 month +2.0%+9.9%+24.0% -2.0%
3 months +0.5%-8.6%+17.0% -2.8%
6 months +19.9%+0.9%+31.7% +2.0%
Year to date +12.4%-11.9%+25.7% +10.6%
1 year +18.4%-17.1%+24.5% +12.2%
3 years —+9.4%+62.9% +68.1%
3 years, per year —+3.0%+17.7% +18.9%
5 years —+17.1%-7.6% +61.4%
5 years, per year —+3.2%-1.6% +10.1%
10 years —+180.5%+253.3% +248.5%
10 years, per year —+10.9%+13.5% +13.3%

Risk

MeasureSOLVSYKEWSPY
Volatility, 1Y 30.1%32.9%25.5% 13.6%
Downside volatility, 1Y 29.3%32.8%24.7% 13.9%
Beta vs S&P 500, 1Y 0.610.280.58 1.00
Return / volatility, 1Y 0.61-0.520.96 0.90
Max drawdown, 5Y -40.0%-33.1%-54.3% -25.4%
From 52-week high -3.7%-20.1%0.0% -3.2%
52-week high $92.45$387.46$107.18 $779.14
52-week low $62.49$269.88$75.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSOLVSYKEW
P/E now vs peer median 97.5xmedian 26.5x 32.7xmedian 26.5x 60.9xmedian 26.5x
P/S now vs peer median 1.9xmedian 2.7x 4.5xmedian 2.7x 9.2xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 38.6xmedian 18.4x 35.8xmedian 18.4x
P/FCF now vs peer median 156.0xmedian 25.4x 25.8xmedian 25.4x 43.3xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 5.0xmedian 2.5x 5.6xmedian 2.5x
PEG now vs peer median —median 0.98 2.76median 0.98 -6.65median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSOLVSYKEW
Revenue $8.16B $26.30B $6.67B
Gross profit $4.47B $17.18B $5.21B
Operating income $454.00M $5.43B $1.44B
Net income $156.00M $3.62B $1.02B
Free cash flow – $4.57B $1.42B
R&D $723.00M $1.68B $1.09B
EPS (diluted) $0.91 $9.42 $1.76
Cash & equivalents $451.00M $3.27B $3.11B
Total debt $5.07B $14.93B $598.80M
Shares (diluted) 170.80M 384.70M 577.60M
Enterprise value $12.84B $104.03B $45.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSOLVSYKEW
P/E 97.5x 32.7x 60.9x
P/FCF 156.0x 25.8x 43.3x
P/Operating cash flow 48.8x 21.6x 35.9x
P/S 1.9x 4.5x 9.2x
P/B 3.1x 5.0x 5.6x
P/Tangible book 6.1x 6.6x 6.3x
EV/EBITDA 20.3x 38.6x 35.8x
EV/EBIT 43.5x 23.8x 40.0x
EV/Revenue 2.4x 4.9x 8.6x
EV/FCF – 28.3x 40.5x
EV/Operating cash flow 63.7x 23.8x 33.6x
PEG (3Y EPS CAGR) – 2.76 -6.65

Growth

14 metrics
MetricSOLVSYKEW
Revenue growth (1Y) -2.8% 7.9% 13.4%
Revenue CAGR (3Y) – 9.8% 16.9%
Gross profit growth (1Y) -1.6% 10.1% 13.2%
Gross profit CAGR (3Y) – 10.9% 13.7%
Operating income growth (1Y) -79.3% 48.2% 1.1%
Operating income CAGR (3Y) – 16.4% 5.8%
Net income growth (1Y) -89.8% 23.1% -25.2%
Net income CAGR (3Y) – 11.9% -10.6%
EPS growth (1Y) -89.5% 23.7% -24.5%
EPS CAGR (3Y) – 11.8% -9.2%
Operating cash flow growth (1Y) -37.1% 12.7% 68.9%
Operating cash flow CAGR (3Y) – 19.6% 18.1%
Free cash flow growth (1Y) – 12.3% 77.1%
Free cash flow CAGR (3Y) – 21.2% 20.8%

Profitability

14 metrics
MetricSOLVSYKEW
Gross margin 54.8% 65.3% 78.0%
EBITDA margin 11.9% 12.8% 24.2%
Operating margin 5.6% 20.7% 21.6%
Pretax margin 2.1% 19.5% 21.5%
Net margin 1.9% 13.8% 15.2%
FCF margin – 17.4% 21.3%
Operating cash flow margin 3.8% 20.7% 25.7%
Return on equity 3.3% -4.0% 9.4%
Return on assets 1.1% -2.0% 7.2%
Return on invested capital 4.2% 10.0% 8.7%
Return on capital employed 4.3% 13.2% 11.6%
Asset turnover 0.6x 0.6x 0.5x
Cash conversion (OCF / net income) 2.0x 1.5x 1.7x
Stock comp / revenue 2.1% 1.0% 2.6%

Financial Health

11 metrics
MetricSOLVSYKEW
Debt / assets 35.8% 31.6% 4.2%
Debt / equity 1.1x 0.6x 0.1x
Net debt / EBITDA 4.7x 3.5x -2.5x
Debt / FCF – 3.3x 0.4x
Liabilities / assets 66.1% 50.4% 22.5%
Equity / assets 33.9% 49.6% 77.5%
Interest coverage – 9.3x –
Current ratio 1.0x 2.2x 4.6x
Quick ratio 0.5x 1.1x 3.5x
Cash ratio 0.1x 0.5x 2.9x
Altman Z-score 1.85 4.73 14.42

Shareholder Returns

7 metrics
MetricSOLVSYKEW
Dividend yield – 1.1% –
Net buyback yield 2.7% – 0.9%
Shareholder yield 2.7% 1.1% 0.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSOLVSYKEW
Forward P/E 12.8xFY2026 19.6xFY2026 37.6xFY2026
EPS, next fiscal year $6.93FY2026 $15.79FY2026 $2.85FY2026
EPS growth, next FY +13.4%FY2026 +15.8%FY2026 +11.3%FY2026
EPS growth, the year after +15.3% +0.9% +12.6%
Revenue, next fiscal year $7.71BFY2026 $25.79BFY2026 $7.28BFY2026
Revenue growth, next FY -7.3%FY2026 +2.7%FY2026 +19.9%FY2026
Revenue growth, the year after +5.8% +16.5% -2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSOLVSYKEW
Held by institutions 73.9% 80.3% 90.6%
Institutions holding 882 2,267 1,326
Change in shares held, QoQ -0.9% +3.1% +20.4%
Institutions buying 370 1,105 641
Institutions selling 286 852 456
Buyers to sellers 1.29 1.30 1.41

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SOLVSYKEW
SOLV 1.00 0.46 0.27
SYK 0.46 1.00 0.44
EW 0.27 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SOLV, SYK and EW?

Stryker (SYK) is the largest by market capitalisation: Solventum (SOLV) $15.13B, Stryker (SYK) $117.84B, Edwards Lifesciences (EW) $61.69B.

Which stock is cheaper, SOLV, SYK and EW?

Stryker (SYK) trades on the lowest price-to-earnings ratio (Solventum (SOLV) 97.5x, Stryker (SYK) 32.7x, Edwards Lifesciences (EW) 60.9x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Solventum (SOLV) 12.8x, Stryker (SYK) 19.6x, Edwards Lifesciences (EW) 37.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Solventum (SOLV) -2.8%, Stryker (SYK) +7.9%, Edwards Lifesciences (EW) +13.4%.

Which company is more profitable?

Edwards Lifesciences (EW) has the highest net margin (Solventum (SOLV) 1.9%, Stryker (SYK) 13.8%, Edwards Lifesciences (EW) 15.2%). On return on invested capital, Stryker (SYK) leads (Solventum (SOLV) 4.2%, Stryker (SYK) 10.0%, Edwards Lifesciences (EW) 8.7%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Solventum (SOLV) +18.4%, Stryker (SYK) -17.1%, Edwards Lifesciences (EW) +24.5%. Over five years, Stryker (SYK) compounded fastest (Stryker (SYK) +3.2%/yr, Edwards Lifesciences (EW) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Stryker (SYK) 1.14%. Solventum (SOLV) and Edwards Lifesciences (EW) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Solventum (SOLV) 30.1%, Stryker (SYK) 32.9%, Edwards Lifesciences (EW) 25.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SOLV, SYK and EW?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Edwards Lifesciences (EW) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.